This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2003 Oct 15;21(20):3718-20.

doi: 10.1200/JCO.2003.07.942. Epub 2003 Sep 8.

Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?

Richard L Schilsky

PMID: 12963701
DOI: 10.1200/JCO.2003.07.942

Editorial

Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?

Richard L Schilsky. J Clin Oncol. 2003.

. 2003 Oct 15;21(20):3718-20.

doi: 10.1200/JCO.2003.07.942. Epub 2003 Sep 8.

Author

Richard L Schilsky

PMID: 12963701
DOI: 10.1200/JCO.2003.07.942

No abstract available

PubMed Disclaimer

Comment on

From access to evidence: an advocate's journey.
Mayer M. Mayer M. J Clin Oncol. 2003 Oct 15;21(20):3881-4. doi: 10.1200/JCO.2003.07.217. J Clin Oncol. 2003. PMID: 14551309 No abstract available.

Similar articles

Accelerated approval seen as triumph and roadblock for cancer drugs.
Susman E. Susman E. J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6. doi: 10.1093/jnci/96.20.1495. J Natl Cancer Inst. 2004. PMID: 15494596 No abstract available.
Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Johnson JR, et al. J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422403 Review.
Accelerated approval of oncology drugs: can we do better?
Ellenberg SS. Ellenberg SS. J Natl Cancer Inst. 2011 Apr 20;103(8):616-7. doi: 10.1093/jnci/djr104. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422401 No abstract available.
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Tsimberidou AM, et al. J Clin Oncol. 2009 Dec 20;27(36):6243-50. doi: 10.1200/JCO.2009.23.6018. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826112 Review.
Accelerated approval of oncology products: a decade of experience.
Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Dagher R, et al. J Natl Cancer Inst. 2004 Oct 20;96(20):1500-9. doi: 10.1093/jnci/djh279. J Natl Cancer Inst. 2004. PMID: 15494600 Review.

See all similar articles

Cited by

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB 3rd, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL. Richey EA, et al. J Clin Oncol. 2009 Sep 10;27(26):4398-405. doi: 10.1200/JCO.2008.21.1961. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636013 Free PMC article.
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.
McPhail M, Weiss E, Bubela T. McPhail M, et al. Front Med (Lausanne). 2022 Feb 3;8:818647. doi: 10.3389/fmed.2021.818647. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35186979 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.